Literature DB >> 20170767

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Michael Vaine1, Shixia Wang, Anthony Hackett, James Arthos, Shan Lu.   

Abstract

Using a gp120 envelope glycoprotein from the JR-FL strain of human immunodeficiency virus-1 (HIV-1) as a model antigen, the goal of the current study was to evaluate the level and quality of antibody responses elicited by different prime-boost vaccination regimens (protein only, DNA only, DNA plus protein) in rabbits. Our data demonstrated that incorporating DNA immunization as a prime in a heterologous prime-boost regimen was able to elicit a more diverse and conformational epitope profile, higher antibody avidity, and improved neutralizing activity than immunization with only protein. Additionally, this improved neutralizing activity was observed in spite of similar antibody specificities and avidities seen when only DNA vaccination was used, providing additional evidence that the use of a combination immunization regimen increases the protective antibody response. Insights gained from the current study confirmed that the heterologous DNA prime-protein boost approach is effective in eliciting not only high level but also improved quality of antigen-specific antibody responses, and thus may offer a new technology platform to develop better and safer subunit vaccines. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20170767      PMCID: PMC2847033          DOI: 10.1016/j.vaccine.2010.02.006

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

Review 1.  Overview of vaccine adjuvants: present and future.

Authors:  Robert L Hunter
Journal:  Vaccine       Date:  2002-05-31       Impact factor: 3.641

2.  Bovine serological response to a recombinant BPV-1 major capsid protein vaccine.

Authors:  X W Jin; L Cowsert; D Marshall; D Reed; W Pilacinski; L Y Lim; A B Jenson
Journal:  Intervirology       Date:  1990       Impact factor: 1.763

3.  Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts.

Authors:  S Ghim; N D Christensen; J W Kreider; A B Jenson
Journal:  Int J Cancer       Date:  1991-09-09       Impact factor: 7.396

4.  Immunization against bovine papillomavirus infection.

Authors:  W P Pilacinski; D L Glassman; K F Glassman; D E Reed; M A Lum; R F Marshall; C C Muscoplat; A J Faras
Journal:  Ciba Found Symp       Date:  1986

5.  Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types.

Authors:  W F Jarrett; B W O'Neil; J M Gaukroger; K T Smith; H M Laird; M S Campo
Journal:  Vet Rec       Date:  1990-05-12       Impact factor: 2.695

6.  Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

Authors:  Jun Zhao; Lilin Lai; Rama Rao Amara; David C Montefiori; Francois Villinger; Lakshmi Chennareddi; Linda S Wyatt; Bernard Moss; Harriet L Robinson
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

7.  Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs.

Authors:  Philip J Hogarth; Keith J Jahans; Rolf Hecker; R Glyn Hewinson; Mark A Chambers
Journal:  Vaccine       Date:  2003-02-14       Impact factor: 3.641

Review 8.  Heterologous prime-boost vaccination.

Authors:  Shan Lu
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

9.  Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.

Authors:  Valicia Burke; Constance Williams; Madhav Sukumaran; Seung-Sup Kim; Huiguang Li; Xiao-Hong Wang; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Structure       Date:  2009-11-11       Impact factor: 5.006

10.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

View more
  57 in total

1.  Coexpressed RIG-I agonist enhances humoral immune response to influenza virus DNA vaccine.

Authors:  Jeremy M Luke; Gregory G Simon; Jonas Söderholm; John S Errett; J Thomas August; Michael Gale; Clague P Hodgson; James A Williams
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

Review 2.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

3.  A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.

Authors:  Zheng Wang; Mingshun Zhang; Yan Wang; Yanmei Jiao; Lu Zhang; Lin Li; Zuhu Huang; Hao Wu; Jingyun Li; Shan Lu; Shixia Wang
Journal:  J Virol Methods       Date:  2010-10-27       Impact factor: 2.014

Review 4.  HIV vaccines: lessons learned and the way forward.

Authors:  Jerome H Kim; Supachai Rerks-Ngarm; Jean-Louis Excler; Nelson L Michael
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

Review 5.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

Review 6.  Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Richard B Kennedy; Iana H Haralambieva; Robert M Jacobson
Journal:  OMICS       Date:  2011-07-06

Review 7.  Clinical applications of DNA vaccines: current progress.

Authors:  Bernadette Ferraro; Matthew P Morrow; Natalie A Hutnick; Thomas H Shin; Colleen E Lucke; David B Weiner
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

8.  A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Authors:  Christine A Bricault; James M Kovacs; Joseph P Nkolola; Karina Yusim; Elena E Giorgi; Jennifer L Shields; James Perry; Christy L Lavine; Ann Cheung; Katharine Ellingson-Strouss; Cecelia Rademeyer; Glenda E Gray; Carolyn Williamson; Leonidas Stamatatos; Michael S Seaman; Bette T Korber; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

9.  The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination.

Authors:  Kristin Hollister; Yuxin Chen; Shixia Wang; Hao Wu; Arpita Mondal; Ninah Clegg; Shan Lu; Alexander Dent
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.